



Bal Pharma Limited

To,
The Manager-Listing
BSE Limited
Mumbai.

6.3.2018

The Manager-Listing
National Stock Exchange of India Ltd
Mumbai.

Dear Sir,

Sub : Press Release.
Ref : Regulation 30 of SEBI (LODR) Regulations.

With reference to the above cited subject and reference, we are submitting to the exchange a copy of the press release on the proposed collaboration of Bal Pharma Ltd with Australian Pharmaceuticals Company i.e Akaal Pharma Pty Ltd, in developing and marketing of veterinary medicine.

The said transaction was approved by the Board of Directors of the Company at their meeting held on 14.02.2018.

Please take the same on record.

Thanking You.

For Bal Pharma Ltd

Shailesh Siroya
Managing Director



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58
Email : info@balpharma.com Website : www.balpharma.com
CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820



Bal Pharma Limited

PRESS RELEASE

AKAAL PHARMA PTY LTD AND BAL PHARMA LTD TO DEVELOP NOVEL VETERINARY THERAPEUTICS

March 6, 2018

Akaal Pharma Pty Ltd, Melbourne, Australia (herein "Akaal Pharma") and Bal Pharma Ltd, Bangalore, India (herein "Bal Pharma") today announce a collaboration and the launch of Joint Venture Company "AB VET Pharma Pty Ltd" (herein "AB VET"). The new joint venture will be completely funded by Bal Pharma to develop Akaal Pharma's IP within the veterinary field.

The first veterinary indication will be against atopic dermatitis (AD) in dogs. Akaal's ABV-119 is the first of its kind oral drug candidate for the treatment of AD in dogs. ABV-119 is a multimodal therapy that includes anti-inflammatory/ immune modulatory and anti-itch effects. AB VET plans to begin clinical development in H1 2018.

"Atopic Dermatitis is a chronic disease affecting pets from early age. ABV-119 addresses significant gaps in the current treatment regimen and has global patent protection. Bal Pharma's extensive global reach and manufacturing capabilities would support the research efforts of Akaal and will strengthen the Joint Venture. We are very excited to co-develop the intellectual property for vet applications and make it available to pet owners globally, said Mr. Shailesh Siroya, Managing Director of Bal Pharma.

"We are pleased to have Bal Pharma as a strategic partner to develop a first-in-class in oral drug treatment against AD in dogs. This partnership further strengthens Akaal Pharma's drug discovery platform and opens the door to new opportunities in the veterinary field", said Mr Bagicha S Sandhu, Chairman of Akaal Pharma.

About Dog Atopic Dermatitis

Atopic dermatitis has underlying multiple pathological features with inflammation, immune hyperactivity and vascular barrier disruption. Dogs with atopic dermatitis are usually itchy. The inflamed lesions and recurrent infections are quite common in these patients. The symptoms usually start at early age when the dog is 1 to 5 years old. There is undermet need of atopic dermatitis for a safe and effective oral drug.



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560 052, India
Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057 / 58

Email : info@balpharma.com Website : www.balpharma.com

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813 / 19 Fax: 41570820

About Akaal Pharma

Akaal Pharma is an Australian clinical-stage drug discovery and development company focused on developing novel drugs for the treatment of inflammation and immune diseases. Akaal through its proprietary drug discovery platform has created a pipeline of anti-inflammatory drugs with multiple applications. Akaal Pharma has strong portfolio of intellectual property/patents on its internally discovered drug candidates. For more information, visit www.akaalpharma.com

About Bal Pharma

Bal Pharma, an Indian Pharmaceutical Company with 25 years of experience, specialized in Prescription Drugs, and Bulk Actives, supplying bulk drugs and formulations across 60 countries through its network. Bal Pharma also brings novel drugs to the market, including Ayurvedic and Herbal medicines.

Contacts:**Bal Pharma Pvt Ltd:**

5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bangalore - 560052. Tel: +91709-026-9000, Email : mdsect@balpharma.com

Akaal Pharma Pty Ltd:

Thomas Cherry Building, #301E, La Trobe University, Bundoora, VIC-3083, Australia. Tel: +61-3-9479-2584. Email: info@akaalpharma.com

Certain statements in this new release concerning Akaal Pharma and Bal Pharma business are considered "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all the forward-looking statements in this press release can be affected by inaccurate assumptions Akaal Pharma or Bal Pharma might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of drug development; uncertainties as to the future success. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Akaal Pharma or Bal Pharma undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.